Chicago Partners Investment Group LLC Increases Stake in Pfizer Inc. $PFE

Chicago Partners Investment Group LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 6.1% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 77,570 shares of the biopharmaceutical company’s stock after buying an additional 4,462 shares during the period. Chicago Partners Investment Group LLC’s holdings in Pfizer were worth $1,967,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. First Bancorp Inc ME increased its holdings in Pfizer by 6.7% during the 2nd quarter. First Bancorp Inc ME now owns 18,215 shares of the biopharmaceutical company’s stock worth $442,000 after purchasing an additional 1,145 shares during the period. TrueMark Investments LLC lifted its position in shares of Pfizer by 3.6% during the 2nd quarter. TrueMark Investments LLC now owns 110,930 shares of the biopharmaceutical company’s stock worth $2,689,000 after purchasing an additional 3,807 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Pfizer during the second quarter worth $9,582,000. Signature Estate & Investment Advisors LLC increased its holdings in Pfizer by 19.3% in the second quarter. Signature Estate & Investment Advisors LLC now owns 22,976 shares of the biopharmaceutical company’s stock valued at $557,000 after buying an additional 3,722 shares during the last quarter. Finally, United Bank raised its stake in Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after buying an additional 6,415 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.52 on Monday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.36. The stock has a 50 day moving average of $24.89 and a two-hundred day moving average of $24.11. The stock has a market cap of $139.38 billion, a P/E ratio of 13.04, a P/E/G ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the firm posted $0.60 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PFE. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. UBS Group restated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Bank of America upped their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Morgan Stanley cut their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.